Learn

Psychedelic medicines are moving from trials into clinics. Here is the evidence behind them, when they could become FDA approved, and the rules that will govern how they are delivered.

The medicines are arriving faster than the places to deliver them.

Esketamine has been dispensed in certified clinics since 2019. Psilocybin, LSD, and MDMA-based therapies have cleared Phase 3 trials, with a further wave behind them. Each molecule will require a certified site, a trained prescriber, and hours of supervised monitoring.

Science

Three classes of medicine, one downstream effect — and a body of controlled-trial evidence in which the therapist is never incidental.

Mechanism

One pathway, three drug classes

Classic psychedelics act on 5-HT2A receptors, MDMA on monoamine and oxytocin release, ketamine on NMDA. Downstream they converge on the same signature: a window of heightened neuroplasticity that scales with the duration of the subjective effects.

PTSD

Two Phase 3 trials, consistent results

In MAPP2 (n=104), 71% of participants no longer met criteria for PTSD at 18 weeks, against 48% receiving placebo with the same therapy. MAPP1 (n=90) found 67% against 32%.

Depression

Endpoints met in treatment-resistant depression

COMP005 (n=258) and COMP006 (n=581) both met their primary endpoint on the MADRS depression scale, with effects durable to 26 weeks in the first trial.

The therapist's role

Therapy is in the protocol, not alongside it

Every one of these trials placed a clinician at the centre — manualised psychotherapy in the PTSD studies, structured psychological support in the depression studies. The medicine opens a window; the therapy is what happens inside it.

Pipeline

A defined commercialisation wave. Nearly every programme in it carries a high likelihood of supervised, on-site administration.

Product	Sponsor	Indication	Status	Est.
Spravato — esketamine	Johnson & Johnson	Treatment-resistant depression	Marketed under REMS	Since 2019
COMP360 psilocybin	Compass Pathways	Treatment-resistant depression	Phase 3 met; rolling NDA	2027
MDMA	Resilient	PTSD	Resubmitted	2027–28
DT120 — LSD	Definium	Depression · anxiety	Positive topline	2028
Psilocybin	Usona Institute	Major depressive disorder	Phase 3 enrolled	2028–29
TSND-201 — methylone	Otsuka	PTSD	Phase 3 underway	2029
BPL-003 — 5-MeO-DMT	atai Beckley	Treatment-resistant depression	Breakthrough Therapy	2029–30

Estimated launch windows reflect sponsor disclosures and are subject to FDA review.

Regulatory

The FDA approves the molecule; a Risk Evaluation and Mitigation Strategy governs the system that delivers it. Four requirements shape what a clinic has to be.

Site certification

Only enrolled settings may dispense

A REMS restricts distribution to healthcare settings that have enrolled and can be audited. It is not something a standard therapy office can opt into.

Prescriber certification

A trained prescriber, tied to a certified site

The prescriber must complete REMS training and be linked to the certified location where dosing happens.

Supervised administration

At least two hours of observation

The Spravato protocol sets the pattern: vitals and contraindications checked before dosing, direct observation throughout, continuous monitoring for at least two hours, and a stable-discharge check before the patient leaves.

Records

Audit-ready documentation

Session-level logs, patient enrolment, and adverse-event reporting, all open to inspection by the FDA and the manufacturer.

What is REMS

A Risk Evaluation and Mitigation Strategy is a program the FDA can require for a medicine with serious risks. Spravato has been dispensed under one since 2019, and the psychedelic therapies are expected to follow; their exact requirements will be set at approval.

Who has to be certified

A dose can only be given when all three are in place, and the prescriber is tied to the specific site where dosing happens.

The REMS programRequired by the FDA, run by the drug’s manufacturer

Certified healthcare settingEnrolled with the program and open to audit
Certified prescriberCompletes REMS training and is linked to that setting
Enrolled patientRegistered with the program before treatment begins

What happens around every dose

The Spravato protocol sets the pattern: four steps, on site, each one documented.

1 · BeforeCheck
Vitals and contraindications reviewed before dosing
2 · DuringObserve
The dose is taken under direct observation
3 · AfterMonitor
Continuous monitoring for at least two hours
4 · LeavingDischarge
A clinician confirms the patient is stable to leave

What it means for you

For prescribers

Your certification, our site

Complete the manufacturer’s REMS training
Link your certification to the Clearlight site
Prescribe and oversee treatment; Clearlight helps to staff the monitoring and coordinate the care

For therapists

Therapy inside a compliant setting

In the psychedelic trials, therapy was part of the protocol
Preparation, dosing-day support and integration happen in rooms built for it
Requirements for the therapist’s role will be set at approval

Clearlight

The certified setting, run for you

Enrolls as the certified healthcare setting
Provides the rooms, monitoring staff and discharge checks
Keeps session logs, patient enrollment and adverse-event reporting audit-ready

← Back to Clearlight